Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease
Advanced solid tumors responded favorably to the combination of rucaparib plus sacituzumab govitecan, in results of the phase 1B SEASTAR study presented at this year’s virtual European Society for Medical Oncology meeting by Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science; associate professor, Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology; and associate director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center.
Watch video Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease online, duration hours minute second in high quality that is uploaded to the channel AJMCtv 25 September 2020. Share the link to the video on social media so that your subscribers and friends will also watch this video. This video clip has been viewed 221 times and liked it 1 visitors.
